Skip to main content
Back
Watch Compare

MiNK Therapeutics, Inc.

Data quality: 83%
INKT
Nasdaq Manufacturing Chemicals
$11.04
▼ $0.43 (-3.75%)
Mkt Cap: 56.46 M
Price
$11.37
Mkt Cap
56.46 M
Day Range
—
52-Week Range
—
Volume
—
Open —
50D / 200D Avg
—
50D / 200D Avg
—

Quick Summary

Key Takeaways

Negative free cash flow of -5.93 M

Growth

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
N/A
ROICN/A
Net MarginN/A
Op. MarginN/A

Safety

Debt / Equity
N/A
Current Ratio1.08
Interest Coverage-114.93

Valuation

PE (TTM)
-4.52
Below sector avg (-1.48)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A

Price History

Financial Trends

Peer Comparison

vs Manufacturing sector median (1364 peers)
Metric Stock Sector Median
P/E -4.5 -1.5
P/B — 1.6
ROE % — -53.5
Net Margin % — -41.5
Rev Growth 5Y % — 1.8
D/E — 0.3

Analyst Price Target

2 analysts
Buy
Current
$11.04
+253.3%
Target
$39.00
$35.00
$39.00
$43.00
Forecast
Forward P/E -3.20
Forward EPS -$3.45
Est. Revenue 0.0

Earnings Estimates

Period EPS Est. Revenue Est. Analysts
FY2027 -$3.45
-$3.58 – -$3.32
 0.0 2
FY2026 -$3.27
-$3.50 – -$3.03
 0.0 2

Earnings Surprises

Last 4 quarters
Quarter Est. EPS Actual EPS Surprise
Q42025 -$0.68 -$0.56 +17.7%
Q32025 -$0.86 -$0.65 +24.0%
Q22025 -$0.55 -$1.06 -93.9%
Q12025 -$0.61 -$0.70 -14.8%

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -12.49 M
ROE N/A ROA -143.22%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -5.93 M
ROIC N/A FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 1.08
Interest Coverage -114.93 Asset Turnover N/A
Working Capital 1.10 M Tangible Book Value -13.51 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -4.52 Forward P/E N/A
P/B Ratio N/A P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -10.49%
Market Cap 56.46 M Enterprise Value 42.18 M
Per Share
EPS (Diluted TTM) -2.93 Revenue / Share N/A
FCF / Share -1.19 OCF / Share -1.19
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 47.42%
SBC-Adj. FCF -8.42 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue — — — — —
Net Income -12.49 M -10.78 M -22.46 M -27.99 M -30.21 M
EPS (Diluted) -2.93 -2.86 -0.65 -0.83 —
Gross Profit — — — — —
Operating Income -12.64 M -11.29 M -22.92 M -30.95 M -28.36 M
EBITDA — — — — —
R&D Expenses 5.76 M 6.34 M 15.49 M 23.12 M 13.97 M
SG&A Expenses — — — — —
D&A — — — — —
Interest Expense -110,000.0 -93,000.0 463,256.0 253,323.0 2.43 M
Income Tax — — — — —

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 14.24 M 5.72 M 4.55 M 21.47 M 40.24 M
Total Liabilities — — — — —
Shareholders' Equity -14.23 M -19.59 M -18.06 M -401,303.0 23.78 M
Total Debt — — — — —
Cash & Equivalents 13.36 M 4.58 M 3.37 M 19.64 M —
Current Assets 13.85 M 4.99 M 3.60 M 20.40 M 39.63 M
Current Liabilities 13.03 M 6.96 M 11.40 M 12.68 M 16.47 M